Amidst the AI boom transforming various sectors, Recursion Pharmaceuticals (NASDAQ: RXRX), a previously beaten-down AI-biotech, is showing signs of a rebound. Its stock has skyrocketed 25% in the past month, capturing market attention after a significant decline over the past year. However, analysts warn it may be too early to conclude a sustained upward trajectory has begun.
Unlike typical biotech firms whose shares rally on specific clinical or regulatory news, Recursion’s recent surge lacks any clear operational announcements. Analysis suggests the move could be attributed to general market volatility, combined with investor anticipation of clinical updates the company is expected to release before year-end.
Recursion’s core advantage lies in its proprietary operating system, which uses AI to virtually screen compounds, aiming to significantly increase the success rate of drug candidates. Industry data indicates that about 90% of candidates that enter clinical trials ultimately fail, with an average cost of $2 billion per approved drug. Recursion claims its AI platform can reduce pre-clinical research costs to just $10 million, far below the industry average of approximately $27 million.
The company’s pipeline currently includes four clinical-stage programs. The most advanced is REC-617, a candidate for solid tumors currently in Phase 1/2 trials. Preliminary data shows promising signs of safety and efficacy in colorectal and lung cancer—the latter being a multi-billion dollar market dominated by blockbusters like Merck’s Keytruda and Bristol Myers Squibb’s Opdivo. If REC-617 proves to have “best-in-class” potential, it would be a strong validation of Recursion’s AI platform against industry giants.
Recursion has secured collaborations with pharmaceutical heavyweights including Merck, Roche, Sanofi, and Bayer. These partnerships not only provide a stable funding source—mitigating a common risk for small biotechs—but also lend credibility to its technology. The company’s long-term strategy involves transitioning toward a high-margin business model by licensing its operating system to other drugmakers.
Despite the promising outlook, investors should note considerable risks:
A notable point for investors is that Recursion is the only biotech stock to receive a direct investment from AI giant Nvidia. While this endorsement boosts its profile, it does not eliminate the fundamental business risks.
Analysts suggest Recursion is suitable only for long-term investors with a high tolerance for volatility. While its current market cap of around $3 billion offers substantial growth potential, the high-risk nature of the biotech sector warrants caution for conservative investors. The company’s planned clinical data releases before the end of 2025 will be critical milestones for assessing the true value of this AI-driven biotech stock.
